Payee	Study Name	/ Lead Researcher	Principal Investigator / Lead Researcher	City of PI / Lead Researcher	State of PI / Lead	Tota
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL	Last Name	First Name		Researcher	
	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
ACHIEVE CLINICAL RESEARCH LLC	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	WILLIAMS	HAYES	BIRMINGHAM	AL	\$8,186.20
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
ADOBE CLINICAL RESEARCH, LLC	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	MOUSSA	SAM	TUCSON	AZ	\$8,897.6
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
AKDHC MEDICAL RESEARCH SERVICE	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	CORTEZ	ANDREW	AVONDALE	AZ	\$25,796.54
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
AKDHC MEDICAL RESEARCH SERVICE	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	FADIA	AMIT	TUCSON	AZ	\$16,696.5
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
AKDHC MEDICAL RESEARCH SERVICE	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	HACHEM	HASSAN	MESA	AZ	\$1,558.3
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	MUSTAFA	ESMAT	PHOENIX	AZ	400 740 5
AKDHC MEDICAL RESEARCH SERVICE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	MUSTAFA	ESIVIAT	PHOENIX	AL	\$26,746.5
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
AKDHC MEDICAL RESEARCH SERVICE	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	NICA	ROMANITA	PRESCOTT	AZ	\$8,606.6
means to resembling service	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM					90,000.04
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
AKDHC MEDICAL RESEARCH SERVICE	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	QURESHI	JUNAID	PHOENIX	AZ	\$18,046.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM					, ,,,
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
AKDHC MEDICAL RESEARCH SERVICE	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SANTOS	PETER	GLENDALE	AZ	\$19,835.54
	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED					
	BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN					
AKRON NEPHROLOGY ASSOCIATES	THE PRESENCE OF SODIUM THIOSULFATE TREATMENT A MULTICENTER REGISTRY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF	RAINA	RUPESH	AKRON	ОН	\$792.81
ALFRED I DUPONT HOSP FOR CHILDREN	MAINTENANCE TREATMENT WITH IRON SUCROSE (VENOFER) IN PEDIATRIC PATIENTS BETWEEN 2 AND 17 YEARS WITH CHRONIC KIDNEY DISEASE	ZARITSKY	JOSHUA	WILMINGTON	DE	\$1,400.00
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM					72,100.0
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
ANTIETAM ONCOLOGY AND HEMATOLOGY	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	HAMDAN	HIND	HAGERSTOWN	MD	\$32,938.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
ASA CLINICAL RESEARCH LLC	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	RABIEI	ABBAS	JUPITER	FL	\$5,321.54
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
ASHEVILLE GASTROENTEROLOGY ASSOCIATES, PA	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	HARLAN	WILLIAM	ASHEVILLE	NC	\$9,821.20
ASHEVILLE GASTROENTEROLOGI ASSOCIATES, FA	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	HARLAN	WILLIAW	ASHEVILLE	NC .	33,021.20
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
ASHLAND-BELLFONTE CANCER CENTER	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	JAIN	KIRTI	ASHLAND	KY	\$1,611.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
ASSOCIATES ON ONCOLOGY AND HEMATOLOGY	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	GANDHI	JITENDRA	CHATTANOOGA	TN	\$11,877.84
ASSOCIATES ON ONCOLOGY AND HEMATOLOGY	OBSERVATIONAL STUDY ON THE USE OF IV IRON THERAPY AMONG SUBJECTS WITH IRON DEFICIENCY ANEMIA	GANDHI	JITENDRA	CHATTANOOGA	TN	\$500.00
222 2.71 2.7 C.T. C.T. COLOUT AND HEIWATOLOGY	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE			- INTERNATION OF THE PARTY OF T		Ç.300.0t
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
ATLANTA GASTROENTEROLOGY ASSOCIATES LLC	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	WOLF	DOUGLAS	ATLANTA	GA	\$30,058.70
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
ATLANTA GASTROENTEROLOGY SPECIALISTS PC	TO INFLAMMATORY BOWEL DISEASE	SALZBERG	BRUCE	SUWANEE	GA	\$28,673.20
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
ATLANTA VANGUARD MEDICAL ASSOCIATES	CENTER SETTING	VARGAS MORRIS	FAYE	SMYRNA	GA	\$187.0
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
BASSETT MEDICAL CENTER	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	FREETH	AMY	COOPERSTOWN	NY	\$3,905.00
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
BLOOD AND CANCER CETNER OF EAST TEXAS	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	GROSS	GARY	TYLER	TX	\$1,071.54
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					1
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
BOND CLINIC, PA	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	HLALAH	OSAMA	WINTER HAVEN	FL	\$1,821.54
BOND CLINIC, PA	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION	HLALAH	OSAMA	WINTER HAVEN	FL	\$1,821.54

Payee	Study Name	Principal Investigator / Lead Researcher	Principal Investigator / Lead Researcher	City of PI / Lead Researcher	State of PI / Lead	Total
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	Last Name	First Name		Researcher	
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
BROOKDALE HOSPITAL MEDICAL CENTER	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	WANG	JEN	BROOKLYN	NY	\$17,825.00
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
BROWARD HEALTH MEDICAL CENTER	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	MAINI	ARCHANA	FT LAUDERDALE	FL	\$1,713.50
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
CANCER CARE CENTERS OF BREVARD	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	ROSS	DAVID	ROCKLEDGE	FL	\$260.10
OWNER O'NE CENTERS OF SHEPPING	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY	11033	D. T. T.	NOCKEE DOL		\$200.10
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
CANCER CARE CENTERS OF BREVARD	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	TAHN	CARL	ROCKLEDGE	FL	\$2,053.54
	A MULTI-CENTER RANDOMIZED OFEN CASEL TRIAL TO EVALUATE THE UTILITY OF SERVIM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION			LAWE OFFICE		40.055.00
CANCER CARE OF NORTH FLORIDA, PA	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	KHAN	WASEEM	LAKE CITY	FL	\$8,365.29
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
CANCER CENTER OF CENTRAL CONNECTICUT	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	BYEFF	PETER	SOUTHINGTON	СТ	\$2,900.54
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
CEDARS-SINAI MEDICAL CENTER	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	MELMED	GIL	LOS ANGELES	CA	\$7,721.25
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
CENTER FOR ADVANCED GASTROENTEROLOGY	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	HILAL	RAOUF	MAITLAND	FL	\$1,287.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
CENTER FOR CANCER AND BLOOD DISORDERS	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	BOCCIA	RALPH	BETHESDA	MD	\$68,361.44
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
CENTRAL TEXAX MEDICAL SPECIALISTS, PLLC	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	DOWNIE	BENJAMIN	AUSTIN	тх	\$6,527.00
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
CHARLESTONE HEMATOLOGY ONCOLOGY ASSOCIATES, PA	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	ORCUTT	JAMES	CHARLESTON	SC	\$967.00
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
CHARLOTTE GASTROENTEROLOGY AND HEPTALOGY, PLLC	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	WILSON	JASON	CHARLOTTE	NC	\$567.00
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
CHEVY CHASE CLINICAL RESEARCH	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	HARDI	ROBERT	CHEVY CHASE	MD	\$10,672.68
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
CHEYENNE REGIONAL MEDICAL CENTER	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	WORKMAN	NATALIE	CHEYENNE	WY	\$1,501.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
CHI ST VINCENT MEDICAL CENTER	CENTER SETTING A MULTICENTER REGISTRY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF	CLEVELAND	LYNN	HOT SPRINGS	AR	\$260.10
CHILDRENS HOSPITAL MEDICAL CENTER	MAINTENANCE TREATMENT WITH IRON SUCROSE (VENOFER) IN PEDIATRIC PATIENTS BETWEEN 2 AND 17 YEARS WITH CHRONIC KIDNEY DISEASE	VANDEVOORDE	RENE	CINCINNATI	ОН	\$2,200.00
	A MULTICENTER REGISTRY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF MAINTENANCE TREATMENT WITH IRON SUCROSE (VENOFER) IN PEDIATRIC PATIENTS					
CLEVELAND CLINIC HOSPITAL	BETWEEN 2 AND 17 YEARS WITH CHRONIC KIDNEY DISEASE A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	DELL	KATHERINE	CLEVELAND	ОН	\$800.00
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
CLINICAL RESEARCH CONSULTANTS, LLC	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	AWAD	AHMED	KANSAS CITY	мо	\$43,540.50
	A BLINDED RANDOMIZED PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND					
CLINICAL RESEARCH SOLUTIONS LLC	SAFETY OF INJECTAFER IN THE TREATMENT OF IRON DEFICIENT PATIENTS WITH FIBROMYALGIA A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	BOOMERSHINE	CHAD	MIDDLEBURG HEIGHTS	ОН	\$345,464.10
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
COMMONWEALTH CLINICAL STUDIES	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	STERN	JERRY	BROCKTON	MA	\$520.20
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
COMPREHENSIVE CANCER CARE CLINIC	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	KHOJASTEH	ALI	JEFFERSON CITY	мо	\$93.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
CONSULTANTS FOR CLINICAL RESEARCH	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	CHOKSHI	MANISH	CINCINNATI	ОН	\$36,049.04
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
DANA-FARBER CANCER INSTITUTE	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	OKAM	MAUREEN	BOSTON	MA	\$19,242.00
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
DAYTON GASTROENTEROLOGY, INC.	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	STONE	LISA	BEAVERCREEK	ОН	\$1,123.20
	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED					
DELAWARE VALLEY NEPHROLOGY	BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	JONES	EDWARD	PHILADELPHIA	PA	\$4,827.73
*********		-	l			,

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Tota
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM					
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
DELTA ONCOLOGY ASSOCIATES	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SHABAZZ	LLOYD	PORTSMOUTH	VA	\$5,896.5
DELIA UNCOLOGI ASSOCIATES	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	SHABAZZ	LLOID	PORTSWOOTH	VA	\$3,630.3
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
DIGESTIVE AND LIVER DISEASE SPECIALISTS	TO INFLAMMATORY BOWEL DISEASE	WOOTTON	TAYLOR	NORFOLK	VA	\$22,913.2
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
DIGESTIVE CARE PHYSICIANS	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	RASHBAUM	STEPHEN	JOHNS CREEK	GA	\$260.1
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
DIGESTIVE HEALTH SPECIALISTS OF SOUTHEAST	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	RUTLAND	TRAVIS	DOTHAN	AL	\$34,323.2
SIGNATURE THE PERSON OF SOUTHERST	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	INOTERIND	TICAVIS	DOTTIAN	n.	JJ4,J2J.2
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
OOCTORS RESEARCH INSTITUTE INC	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	GONZALEZ	MISAEL	MIAMI	FL	\$2,185.0
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
DOYLE, NATALIE	CENTER SETTING	DOYLE	NATALIE	WILSON	NC	\$17,410.0
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
DEVEL LINIVERSITY COLLEGE OF MEDICINE	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION	CTVLED	MICHAEL	DHII ADEI DHIA	DA	¢7.020.1
PREXEL UNIVERSITY COLLEGE OF MEDICINE	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	STYLER	MICHAEL	PHILADELPHIA	1.4	\$7,929.1
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
ASTCHESTER CENTER FOR CANCER CARE	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE LITHITY OF SERLIM	VOLTERRA	FABIO	BRONX	NY	\$6,828.0
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
ASTERN INSTITUTE OF MEDICAL SCIENCES PLLC	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	BURKE	LILLIAN	GREENVILLE	NC	\$5,198.6
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM					40,200
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
ASTERN NEPHROLOGY ASSOCIATES	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	MONTERO	MANUEL	NEW BERN	NC	\$9,606.5
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
L PORTAL CANCER INSTITUTE	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	MALIK	IMTIAZ	MERCED	CA	\$13,803.5
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE					
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
NDOSCOPIC MICROSURGERY ASSOCIATES, PA	TO INFLAMMATORY BOWEL DISEASE	NOAR	MARK	TOWSON	MD	\$3,060.7
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
LORIDA HEALTH CENTER RESEARCH	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	GERSHENBAUM	BART	FT LAUDERDALE	FL	\$9,271.5
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM					
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					_
LORIDA MEDICAL CLINIC, PA	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	MCDONOUGH	RICHARD	ZEPHYRHILLS	FL	\$2,171.5
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
SABRAIL CANCER CENTER RESEARCH	CENTER SETTING	GABRAIL	NASHAT	CANTON	он	\$3,693.5
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
SASTRO CENTER OF MARYLAND	TO INFLAMMATORY BOWEL DISEASE	RAI	RUDRAJIT	COLUMBIA	MD	\$927.0
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
SASTROENTEROLOGY GROUP OF NAPLES	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISFASE	PHILLIPS	RAYMOND	NAPLES	FI	\$4,090.2
ELECTION OF MARKET	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE				1.2	Ç••,U⊃U.2
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
SASTROENTEROLOGY ASSOCIATES CLINICAL RESEARCH	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	номоку	DOUGLAS	KINGSPORT	TN	\$1,192.0
-	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE					
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
SASTROENTEROLOGY ASSOCIATES OF CENTRAL GEORGIA	TO INFLAMMATORY BOWEL DISEASE	SEDGHI	SHAHRIAR	MACON	GA	\$1,123.2
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
ACTROCNITEDOLOGY LTD	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY	CTOCKWEL:	DAV#D	MIDCINIA STACE		640.40
SASTROENTEROLOGY LTD.	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	STOCKWELL	DAVID	VIRGINIA BEACH	VA	\$12,177.1
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
SASTROENTEROLOGY RESEARCH OF LIMA	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	RINESMITH	SCOTT	LIMA	ОН	\$5,613.2
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE		-		1	75,013.2
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
SASTROENTEROLOGY RESEARCH OF SAN ANTONIO	TO INFLAMMATORY BOWEL DISEASE	RANDALL	CHARLES	SAN ANTONIO	TX	\$30,536.4
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
GASTROENTEROLOGY RESEARCH OF THE BAY AREA	TO INFLAMMATORY BOWEL DISEASE	STOLLMAN	NEIL	OAKLAND	CA	\$260.1
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY			T. 1000		4
	TO INFLAMMATORY BOWEL DISEASE	CONTRERAS	BRYAN	TUCSON	AZ	\$27,366.2
SASTROENTEROLOGY RESEARCH OF TUCSON						
SASTROENTEROLOGY RESEARCH OF TUCSON	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
SASTROENTEROLOGY RESEARCH OF TUCSON	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM					

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	Last Name	First Name		Researcher	
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
GLENDALE MEMORIAL HOSPITAL	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	UCAR	KALUST	GLENDALE	CA	\$3,500.00
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
CLODAL CANCED DESCADELLINISTITLITE	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION	D. II	LVAINE	CHROY	C4	602.54
GLOBAL CANCER RESEARCH INSTITUTE	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	BUI	LYNNE	GILROY	CA	\$93.54
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION	CUTTER		0051751116		442 570 74
GREAT FALLS CLINIC, LLP	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	GUTER	KARL	GREAT FALLS	MT	\$12,678.74
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
GREAT LAKES GASTROENTEROLOGY RESEARCH	TO INFLAMMATORY BOWEL DISEASE	FRIEDENBERG	KEITH	MENTOR	ОН	\$7,573.20
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
HEALING HANDS ONCOLOGY AND MEDICAL CARE	CENTER SETTING	АТТОН	MICHAEL	LAWNDALE	CA	\$21,510.00
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
HEALING HANDS ONCOLOGY AND MEDICAL CARE	CENTER SETTING	WALLACE	OLUKEMI	LAWNDALE	CA	\$1,911.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
HEMATOLOGY AND ONCOLOGY ASSOCIATES, INC.	CENTER SETTING	HAUT	MITCHELL	CANTON	ОН	\$10,981.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY			1		
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
HEMATOLOGY ONCOLOGY CLINIC	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	CASTINE	MICHAEL	BATON ROUGE	LA	\$18,156.54
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
HENRY FORD HOSPITAL	CENTER SETTING	KURIAKOSE	PHILIP	DETROIT	MI	\$11,255.00
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
HOPE MEDICAL RESEARCH, INC	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	MOQUETE	MARIO	KISSIMMEE	FI	\$3,185.00
TOTAL MEDICAL RESEARCH, INC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	MOQUETE	10000	MOSIWINE		\$3,103.00
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
HOPE MEDICAL RESEARCH, INC	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	TABREZ	SHAMS	KISSIMMEE	FL	\$5,845.08
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
ILLINOIS CANCER SPECIALISTS	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	MALHOTRA	RAJAT	ARLINGTON HEIGHTS	IL	\$5,466.54
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
INFUSION ASSOCIATES, PC	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	NEDD	KHAN	GRAND RAPIDS	MI	\$23,592.00
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
IRONWOOD PHYSICIANS PC	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	KALMADI	SUJITH	CHANDLER	AZ	\$3,109.54
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
IRONWOOD PHYSICIANS PC	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	SHTIVELBAND	MIKHAIL	CHANDLER	AZ	\$3,211.54
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
JOHN B ARCHBOLD MEMORIAL HOSPITAL	CENTER SETTING A MULTICENTER REGISTRY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF	COLEMAN	TERESA	THOMASVILLE	GA	\$5,621.54
JOHNS HOPKINS UNIVERSITY	MAINTENANCE TREATMENT WITH IRON SUCROSE (VENOFER) IN PEDIATRIC PATIENTS BETWEEN 2 AND 17 YEARS WITH CHRONIC KIDNEY DISEASE	NEU	ALICIA	BALTIMORE	MD	\$2,800.00
	A PLACEBO-CONTROLLED DOUBLE-BLIND CROSSOVER STUDY TO EVALUATE THE EFFICACY OF					1-,
JOHNS HOPKINS UNIVERSITY	KETOROLAC NASAL SPRAY (SPRIX) AS COMPARED TO SUMATRIPTAN NASAL SPRAY AND PLACEBO FOR THE ACUTE ABORTIVE TREATMENT OF MIGRAINE ATTACKS	PETERLIN	BARBARA	BALTIMORE	MD	\$28,625.00
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
JOLIET ONCOLOGY HEMATOLOGY ASSOCIATES	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SIVARAJAN	KULUMANI	JOLIET	IL	\$59,732.89
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
JONES CLINIC PC	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	JONES	CLYDE	GERMANTOWN	TN	\$1,110.54
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
JONES CLINIC PC	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	JONES	CLYDE	GERMANTOWN	TN	\$8,100.00
SONES CLINIC PC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	JOINES	CLIDE	GERIVIANTOWN	LIN	οδ,1UU.UU
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON			1		
VINCTON MEDICAL CRECIALICES DA	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION	MARILLEY	MARK	VINISTON	NC	624.045.5
KINSTON MEDICAL SPECIALISTS PA	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	MARILLEY	MARK	KINSTON	NC	\$34,046.54
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY			1		
KINSTON MEDICAL SPECIALISTS PA	TO INFLAMMATORY BOWEL DISEASE	MARILLEY	MARK	KINSTON	NC	\$1,442.25
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	1				
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
KOSAIR CHILDREN'S HOSPITAL MATERNAL FETAL MEDICINE	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					

Payee	Study Name	Principal Investigator / Lead Researcher	Principal Investigator / Lead Researcher	City of PI / Lead Researcher	State of PI / Lead	Tota
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	Last Name	First Name	i teatai chei	Researcher	
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
LAFAYETTE GENERAL MEDICAL CENTER	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	ARTERBURN	JAMES	LAFAYETTE	LA	\$1,452.10
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
LAKE RESEARCH, LLC	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	ROMAN	ELOY	MIAMI LAKES	FL	\$843.54
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
LANCACTED CANCED CENTED LTD	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	DECREEN	LIVATT	LANCACTER	24	£2.050.54
LANCASTER CANCER CENTER LTD LOMA LINDA UNIVERSITY ADVENTIST HEALTH SCIENCES	A HISTOMORPHOMETRIC ANALYSIS OF BONE FORMATION WITH THREE DIFFERENT BONE	DEGREEN	HYATT	LANCASTER	PA	\$3,058.54
CENTER	GRAFT MATERIALS FOLLOWING SINUS AUGMENTATION A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	KAN	JOSEPH	LOMA LINDA	CA	\$29,965.00
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
LOUISIANA RESEARCH CENTER LLC	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	JOHNSON	LAWRENCE	SHREVEPORT	LA	\$18,859.10
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
MARY HITCHCOCK MEMORIAL HOSP	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	SIEGEL	COREY	LEBANON	NH	\$45,632.25
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
MEDICAL RESEARCH CENTER OF CONNECTICUT	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	GINSBURG	PHILIP	HAMDEN	ст	\$11,177.20
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
MEMORIAL CLINICAL RESEARCH	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	BARRETO	ANGELIQUE	OKLAHOMA CITY	ОК	\$9,893.04
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY				1	
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
MERCY CLINIC, INC.	CENTER SETTING	кота	MANJUSHA	HOT SPRINGS	AR	\$93.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
MONTEFIORE MEDICAL CENTER	CENTER SETTING A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR	CHAITOWITZ	MARK	BRONX	NY	\$14,275.00
	THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN					
NEPHROLOGY AND HYPERTENSION ASSOCIATES OF NJ	THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	PITONE	JOSEPH	VOORHEES	NJ	\$780.75
	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED					
NEPHROLOGY ASSOCIATES OF NORTHERN INDIANA	BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	OSHAUGHNESSY	ANDREW	FT WAYNE	IN	\$5,333.84
	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED					
NEPHROLOGY CONSULTANTS, LLC	BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	QUADRINI	MICHAEL	HUNTSVILLE	AL	\$6,279.96
	CLINICAL AND HISTOLOGICAL EVALUATIONS OF OSSIF-EM DEMINERALIZED ALLOGRAFT STRIP					
NEVINS, MYRON	FOR ALVEOLAR RIDGE AUGMENTATION PROCEDURES A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	NEVINS	MYRON	SWAMPSCOTT	MA	\$132,512.00
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
NORTH MISSISSIPPI HEMATOLOGY AND ONCOLOGY ASSOCIATES	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CROOT	CHRISTOPHER	TUPELO	MS	\$12,776.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					,,······
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
NORTH MISSISSIPPI HEMATOLOGY AND ONCOLOGY ASSOCIATES	CENTER SETTING	HILL	JULIAN	TUPELO	MS	\$260.10
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES	CENTER SETTING A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR	СНИ	DAVID	EAST SETAUKET	NY	\$25,436.64
	THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN					
NORTHEAST CLINICAL RESEARCH CENTER, LLC	THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	KOPYT	NELSON	BETHLEHEM	PA	\$6,482.16
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
NORTHWEST ALABAMA CANCER CENTER	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	PATEL	HEMANT	MUSCLE SHOALS	AL	\$30,631.54
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
NORTHWEST GASTROENTEROLOGY ASSOCIATES	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	WOHLMAN	ROBERT	BELLEVUE	WA	\$8,218.20
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
NORTHWEST GASTROENTEROLOGY CLINIC	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	GALEN	EDWARD	PORTLAND	OR	\$638.10
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL				-	7000.00
NYU LANGONE LONG ISLAND CLINICAL RESEARCH	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
ASSOCIATES	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	TEPPER	ROBERT	GREAT NECK	NY	\$16,989.50
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
OCEAN BLUE MEDICAL RESEARCH CENTER, INC.	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	TERRELONGE	ANTONIO	MIAMI SPRINGS	FL	\$2,133.40
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
OMEGA RESEARCH CONSULTANTS	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	NAIR	SANTOSH	DEBARY	FL	\$8,381.54
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
ODCHADD HEAITHCADE DECEADOU INC	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	OLIFF	IDA	SKOKIE		\$4 343 F4
ORCHARD HEALTHCARE RESEARCH INC	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	OLIFF	IRA	DRURIE	IL.	\$1,243.54
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
OREGON CLINIC PC	TO INFLAMMATORY BOWEL DISEASE	GRUNKEMEIER	DAVID	PORTLAND	OR	\$18,590.00

Payee	Study Name	Principal Investigator / Lead Researcher	Principal Investigator / Lead Researcher	City of PI / Lead Researcher	State of PI /	Total
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	Last Name	First Name		Researcher	
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
PACIFIC CANCER MEDICAL CENTER, INC.	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CHARU	VEENA	ANAHEIM	CA	\$15,073.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
PANDIT, LALITA	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	PANDIT	LALITA	FOUNTAIN VALLEY	CA	\$1,310.04
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
PASTEUR MEDICAL RESEARCH, PLLC	TO INFLAMMATORY BOWEL DISEASE PREVALENCE AND TREATMENT OF IRON DEFICIENCY IN ULCERATIVE COLITIS PATIENTS BY	PHO	HOAN	SAN ANTONIO	TX	\$260.10
PHILADELPHIA VA MEDICAL CENTER	SEVERITY OF DISEASE A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	KHAN	NABEELA	HOUSTON	TX	\$12,000.00
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
PORTER ADVENTIST HOSPITAL	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	KENNEY	THOMAS	DENVER	СО	\$15,425.00
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
REGIONAL CANCER CARE ASSOCIATES	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	ZRADA	STEPHEN	CHERRY HILL	NJ	\$1,740.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
RENAL ASSOCIATES OF BATON ROUGE	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	ROPPOLO	MICHAEL	BATON ROUGE	LA	\$4,306.54
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) V.S. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
SAN ANTONIO GASTROENTEROLOGY ASSOCIATES	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	BULLOCK	JEFF	SAN ANTONIO	TX	\$14,298.60
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
SANTEE HEMATOLOGY ONCOLOGY INC	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	CLOWNEY	BILLY	SUMTER	sc	62 424 54
SANTEE HEMATOLOGY UNCOLOGY INC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	CLOWNEY	BILLT	SUMTER	SC	\$3,421.54
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
SHAYE, OMID	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	SHAYE	OMID	WEST HILLS	CA	\$2,123.54
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
SIOUX LAND HEMATOLOGY-ONCOLOGY ASSOCIATES, LLP	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	WENDER	DONALD	SIOUX CITY	IA	\$12,540.00
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
SOUTH BAY CENTER FOR GI RESEARCH	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	ZAIDEL	OREN	TORRANCE	CA	\$1,123.20
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
SOUTH CAROLINA CANCER SPECIALISTS	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CENTER SETTING	THOMAS	GARY	HILTON HEAD ISLAND	sc	\$4,440.60
SOOTH GINGLING GINGLING EGNESTS	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED	1110111110	0.111	THE FOR THE TOTAL	50	\$4,440.00
SOUTH MISSISSIPPI MEDICAL RESEARCH, LLC	BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	LANIER	DOUGLAS	GULFPORT	MS	\$567.00
SOOTH WISSISSIPPI WESTCAL RESEARCH, EEC	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY	CAMER	DOGLAS	GOEFFORT	IVIS	\$307.00
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
SOUTHEAST MISSOURI HOSPITAL	CENTER SETTING	MOSLEY	JAMES	CAPE GIRADEAU	мо	\$7,021.54
	A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SODIUM THIOSULFATE FOR THE TREATMENT OF PAIN ASSOCIATED WITH CALCIFIC UREMIC ARTERIOLOPATHY FOLLOWED					
SOUTHERN CLINICAL RESEARCH GROUP, LLC	BY A SINGLE ARMED EXTENSION PHASE TO PROSPECTIVELY OBSERVE LESION PROGRESSION IN THE PRESENCE OF SODIUM THIOSULFATE TREATMENT	HOPKINS	ERICA	GULFPORT	LA	\$260.10
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
ST JOSEPH HERITAGE HEALTHCARE	CENTER SETTING A MULTICENTER REGISTRY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF	HOLMES	JARROD	SANTA ROSA	CA	\$6,335.54
STANFORD HOSPITAL & CLINICS	MAINTENANCE TREATMENT WITH IRON SUCROSE (VENOFER) IN PEDIATRIC PATIENTS BETWEEN 2 AND 17 YEARS WITH CHRONIC KIDNEY DISEASE	WONG	CYNTHIA	STANFORD	CA	\$800.00
	A DOUBLE-BLIND MULTI-CENTER RANDOMIZED PLACEBO CONTROLLED STUDY TO INVESTIGATE					
SYNERGY SAN DIEGO	THE EFFICACY AND SAFETY OF INJECTAFER IN THE TREATMENT OF RESTLESS LEG SYNDROME A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	BARI	MOHAMMED	NATIONAL CITY	CA	\$2,567.00
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
TEXAS DIGESTIVE DISEASE CONSULTANTS	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	JAIN	RAJEEV	DALLAS	TX	\$1,192.00
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
TEXAS DIGESTIVE DISEASE CONSULTANTS	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	RITTER	ТІМОТНҮ	SOUTHLAKE	TX	\$1,452.10
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
THE CENTER FOR GASTROINTESTINAL DISORDERS	TO INFLAMMATORY BOWEL DISEASE	LAMET	MARK	HOLLYWOOD	FL	\$7,772.68
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY FEFFET ON LINEAR SECONDAL SERVICE OF THE SAFETY OF THE S					
THE PENALTENNIAL THE POD ASSOCIATION OF STANKING	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION CONTRACTOR IN A CONTRACTOR OF THE CONTRACTOR OF THE CONTRACT	CIMANAINIA	ADUM	MAANULACCE=	NIV	647 070 -
THE FEINSTEIN INSITUTE FOR MEDICAL RESEARCH	CENTER SETTING A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	SWAMINATH	ARUN	MANHASSET	NY	\$17,278.74
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
THE GASTROENTEROLOGY GROUP OF SOUTH JERSEY	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	IZANEC	JAMES	VINELAND	NJ	\$359.48
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
	TO INCLASE AND AND POLICE DISCLASS	ARSENESCU	RAZVAN	COLUMBUS	ОН	\$5,343.00
THE OHIO STATE UNIVERSITY HOSPITAL	TO INFLAMMATORY BOWEL DISEASE A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	ARSENESCO	NAZVAN	COLONIDOS		
THE OHIO STATE UNIVERSITY HOSPITAL		ARSENESCU	RAZVAIV	COLONIDOS		

Payee	Study Name	Principal Investigator / Lead Researcher	Principal Investigator / Lead Researcher	City of PI / Lead Researcher	State of PI / Lead	Total
		Last Name	First Name		Researcher	
THE PENNSYLVANIA STATE UNIVERSITY	OBSERVATIONAL STUDY ON THE USE OF IV IRON THERAPY AMONG SUBJECTS WITH IRON DEFICIENCY ANEMIA	VERMA	NAVIN	HERSHEY	PA	\$1,250.00
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM					
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
TRI-COUNTY HEMATOLOGY AND ONCOLOGY ASSOCIATES	CENTER SETTING	NAGAJOTHI	NAGAPRASAD	MASILLION	ОН	\$13,276.54
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
TRI-STATE GASTROENTEROLOGY ASSOCIATES	TO INFLAMMATORY BOWEL DISEASE	JONES	MICHAEL	CRESTVIEW HILLS	KY	\$1,123.20
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE					
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
TROY GASTROENTEROLOGY CENTER FOR DIGESTIVE HEALTH		WEBER	JOHN	TROY	MI	\$15,005.20
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM					
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					1
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
TYLER HEMATOLOGY ONCOLOGY	CENTER SETTING	DRODER	ROBERT	TYLER	TX	\$2,178.00
	USE OF RECOMBINANT HUMAN PLATELET-DERIVED GROWTH FACTOR-BB AND SYNTHETIC BETA					72,210.00
	TRICALCIUM PHOSPHATE IN INTRAOSSEOUS PERIODONTAL DEFECTS ACCESSED WITH DOUBLE					1
UNIVERSITY OF CONNECTICUT HEALTH CENTER	OR SINGLE FLAP APPROACH: A MULTICENTER RANDOMIZED CONTROLLED TRIAL	SCHINCAGLIA	GIAN	FARMINGTON	СТ	\$18,332.00
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE					
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					1
	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	TO INFLAMMATORY BOWEL DISEASE	ISAACS	KIM	CHAPEL HILL	NC	\$46,325.84
	IRON CLAD - CAN IRON LESSEN ANEMIA DUE TO CANCER AND CHEMOTHERAPY: A MULTI- CENTER RANDOMIZED DOUBLE-BLIND CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND					1
UNIVERSITY CANCER INSTITUTE	SAFETY OF INJECTAFER	NIEDERMAN	THOMAS	BOYNTON BEACH	FL	\$9,820.54
ONVERSITY OUTCER INSTITUTE	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM	MEDERMAN	11101111111	DOTITION DETICIT	1.5	Ç5,020.54
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					1
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
UNIVERSITY CANCER INSTITUTE	CENTER SETTING	THE	ANGELINA	BOYNTON BEACH	FL	\$18,320.00
	A SINGLE ARM OPEN LABEL STUDY TO COMPARE THE PHARMACOKINETICS SAFETY AND					1
LINE SPORTS OF COLORADO DENIES	EFFICACY OF SPRIX IN 12 TO 17 YEAR OLD PATIENTS VS. ADULT PATIENTS 18-64 YEARS	011010714416				400.004.00
UNIVERSITY OF COLORADO DENVER	UNDERGOING OPEN SURGICAL PROCEDURES A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE	CHRISTIANS	UWE	AURORA	со	\$93,031.88
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					1
UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	TO INFLAMMATORY BOWEL DISEASE	ALI	TAUSEEF	OKLAHOMA CITY	ок	\$5,100.00
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE					
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY					1
UNIVERSITY OF SOUTHERN ALABAMA	TO INFLAMMATORY BOWEL DISEASE	CASH	BROOKS	MOBILE	AL	\$14,250.00
	A MULTI-CENTER RANDOMIZED OPEN-LABEL CONTROLLED STUDY TO INVESTIGATE THE					1
	TREATMENT RESPONSE OF INTRAVENOUS INJECTAFER (FERRIC CABOXYMALTOSE) VS. ORAL					
WAKE RESEARCH ASSOCIATES	IRON TO BASELINE HEPCIDIN LEVELS IN PATIENTS WITH IRON DEFICIENCY ANEMIA SECONDARY TO INFLAMMATORY BOWEL DISEASE	BARISH	CHARLES	RALEIGH	NC	\$7,023.20
WALLACE, STEPHEN	EXTRACTION SOCKET PRESERVATION RIDGE AUGMENTATION	WALLACE	STEPHEN	WILMINGTON	NC	\$9,514.50
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM					70,021100
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					1
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON					
	STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
WAVERLY HEMATOLOGY ONCOLOGY	CENTER SETTING	KIRBY	SUZANNE	CARY	NC	\$11,543.30
	A MULTI-CENTER RANDOMIZED OPEN LABEL TRIAL TO EVALUATE THE UTILITY OF SERUM					
	HEPCIDIN LEVELS TO PREDICT RESPONSE TO ORAL OR IV IRON AND COMPARE THE SAFETY					1
	EFFECT ON QUALITY LIFE AND RESOURCE UTILIZATION OF INJECTAFER VS. INTRAVENOUS IRON STANDARD OF CARE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AN INFUSION					
WEST KENTUCKY HEMATOLOGY AND ONCOLOGY GROUP	CENTER SETTING	SKINNER	WILLIAM	PADUCAH	KY	\$93.54
					l.,,	\$55.54